Medical Advocates
Atazanavir (Reyataz)
 
Journal Citations

General Reports                   Therapeutic Strategies
 In Vitro Studies                    Dosage 
Economics                           Pharmacogenetics
 Pharmacokinetics
 Resistance
 Drug/Drug Interactions
 Drug Comparison Studies
 Efficacy
 Diagnostics/Monitoring
 Adverse Events
 Viral Dynamics
 Adherence

  
Atazanavir Main Page New/Newsworthy Home Page      
Last updated:  May 09, 2012
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
General Reports
       
 
Economic and Health-related Quality of Life (HRQL) Comparison of Lopinavir/ritonavir (LPV/r) and
Atazanavir plus Ritonavir (ATV+RTV) based Regimens for Antiretroviral Therapy (ART)-Naďve and -
Experienced United Kingdom (UK) Patients in 2011.
Simpson K, Baran R, Collomb D,  et al
J Med Econ. 2012 May 7.
 Abstract

Ritonavir boosting dose reduction from 100 to 50 mg does not change the atazanavir steady-state exposure
in healthy volunteers.
Estévez JA, Moltó J, Tuneu L,  et al
J Antimicrob Chemother. 2012 May 7.
 Abstract

In vivo Enhancement in Bioavailability of Atazanavir in the Presence of Proton-Pump Inhibitors using Mesoporous Materials.
Xia X, Zhou C, Ballell L, Garcia-Bennett AE.
 ChemMedChem. 2011 Dec 5.
 Abstract

Non-linear mixed effects modeling of antiretroviral drug response after administration of lopinavir, atazanavir and efavirenz
containing regimens to treatment-naďve HIV-1 infected patients.
 Röshammar D, Simonsson US, Ekvall H, et al
J Pharmacokinet Pharmacodyn. 2011 Oct 2.
Abstract

Randomized comparison of metabolic and renal effects of saquinavir/r or atazanavir/r plus tenofovir/emtricitabine in
treatment-naďve HIV-1-infected patients.
 Vrouenraets S, Wit F, Fernandez Garcia E, et al
HIV Med. 2011 Aug 7.
Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Atazanavir concentration in hair is the strongest predictor of outcomes on
antiretroviral therapy.
 Gandhi M, Ameli N, Bacchetti P, et al
Clin Infect Dis. 2011 May;52(10):1267-75.
 Abstract

HIV-Infected Adolescents: Relationship Between Atazanavir Plasma Levels and Bilirubin
Concentrations.
 Nso AP, Larru B, Bellón JM,  et al
J Adolesc Health. 2011 Jan;48(1):100-2'
 Abstract
 

Atazanavir metabolism according to CYP3A5 status: An in vitro - in vivo assessment.
 Wempe MF, Anderson PL.
Drug Metab Dispos. 2010 Dec 9.
 Abstract

Comparison of the influence of four classes of HIV antiretrovirals on adipogenic
differentiation: the minimal effect of raltegravir and atazanavir.
Minami R, Yamamoto M, Takahama S,  et al  
J Infect Chemother. 2010 Aug 13.
 Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Protease inhibitors atazanavir, lopinavir and ritonavir are potent blockers, but
poor substrates, of ABC transporters in a broad panel of ABC transporter-
overexpressing cell lines.
 Bierman WF, Scheffer GL, Schoonderwoerd A,  et al
J Antimicrob Chemother. 2010 Jun 15
 Abstract

Differential Effects of Efavirenz, Lopinavir/r, and Atazanavir/r on the Initial Viral Decay
Rate in Treatment Naďve HIV-1-Infected Patients.
 Edén A, Andersson LM, Andersson O, et al
AIDS Res Hum Retroviruses. 2010 May 10.
 Abstract

The relation between treatment outcome and efavirenz, atazanavir or lopinavir
exposure in the NORTHIV trial of treatment-naďve HIV-1 infected patients.
Josephson F, Andersson MC, Flamholc L, et al 
Eur J Clin Pharmacol. 2010 Apr;66(4):349-57
 Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Effect of ritonavir and atazanavir on human subcutaneous preadipocyte proliferation
and differentiation.
 Caso G, Mileva I, McNurlan MA, et al
Antiviral Res. 2010 Feb 10
 Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Factors influencing lopinavir and atazanavir plasma concentration.
 Stöhr W, Back D, Dunn D, et al
J Antimicrob Chemother. 2009 Nov 6.
Abstract

Trends in uptake of recently approved antiretrovirals within a national healthcare system.
Belperio P, Mole L, Boothroyd D, Backus L.
HIV Med. 2009 Oct 23.
 Abstract

Changes in Body Composition with Ritonavir-Boosted and Unboosted Atazanavir Treatment
in Combination with Lamivudine and Stavudine: A 96-Week Randomized, Controlled Study.
 McComsey G, Rightmire A, Wirtz V, et a,
Clin Infect Dis. 2009 Mar 20.
Abstract
 
A WEEK IN REVIEW FEATURED REPORT
Low atazanavir concentrations in cerebrospinal fluid.
 Best BM, Letendre SL, Brigid E, et al
AIDS. 2009 Jan 2;23(1):83-87.
 Abstract
 
The effect of atazanavir and atazanavir/ritonavir on UDP-glucuronosyltransferase using lamotrigine
as a phenotypic probe.
 Burger DM, Huisman A, Van Ewijk N, et al  
Clin Pharmacol Ther. 2008 Dec;84(6):698-703.
 Abstract
 
Atazanavir: its role in HIV treatment.
 Wood R.  
Expert Rev Anti Infect Ther. 2008 Dec;6(6):785-96.
 Abstract
 
Comparison of ABC Transporter Modulation by Atazanavir in Lymphocytes and Human Brain Endothelial Cells:
ABC Transporters Are Involved in the Atazanavir-Limited Passage across an in Vitro Human Model of the
Blood-Brain Barrier.
Bousquet L, Roucairol C, Hembury A, et al 
AIDS Res Hum Retroviruses. 2008 Aug 26.
 Abstract
 
No impairment of endothelial function or insulin sensitivity with 4 weeks of the HIV protease inhibitors
atazanavir or lopinavir-ritonavir in healthy subjects without HIV infection: a placebo-controlled trial.
 Dubé MP, Shen C, Greenwald M, Mather KJ.
Clin Infect Dis. 2008 Aug 15;47(4):567-74.
 Abstract
 
Effect of atazanavir and ritonavir on the differentiation and adipokine secretion of human subcutaneous
and omental preadipocytes.
 Jones SP, Waitt C, Sutton R, Back DJ, Pirmohamed M.
AIDS. 2008 Jul 11;22(11):1293-8.
 Abstract
 
The Effect of Atazanavir and Atazanavir/Ritonavir on UDP-Glucuronosyltransferase Using Lamotrigine
as a Phenotypic Probe.
 Burger D, Huisman A, Van Ewijk N, et al 
Clin Pharmacol Ther. 2008 Jun 4.
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
Cardiovascular risk score change in HIV-1-infected patients switched to an atazanavir-based
combination antiretroviral regimen.
 Colafigli M, Di Giambenedetto S, Bracciale L 
HIV Med. 2008 Jan 21
Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
The Genotypic Inhibitory Quotient: A Predictive Factor of Atazanavir Response in HIV-1-Infected
Treatment-Experienced Patients.
 Solas C, Colson P, Ravaux I, et al
 J Acquir Immune Defic Syndr. 2008 Jan 11
Abstract
 
Evolution of the HIV-1 protease region in heavily pretreated HIV-1 infected patients
receiving Atazanavir.
 Vergani B, Cicero ML, Vigano' O, et al
J Clin Virol. 2007 Nov 13;
 Abstract
 
HIV-1 Protease Inhibitors Nelfinavir and Atazanavir Induce Malignant Glioma Death
by Triggering Endoplasmic Reticulum Stress.
 Pyrko P, Kardosh A, Wang W, et al 
Cancer Res. 2007 Nov 15;67(22):10920-10928
Abstract
 
Atazanavir: simplicity and convenience in different scenarios.
 Perez-Elias MJ.
Expert Opin Pharmacother. 2007 Apr;8(5):689-700.
Abstract
 
FULL TEXT PDF ARTICLE
 Pharmaceutical Approach to HIV Protease Inhibitor Atazanavir for Bioavailability
Enhancement Based on Solid Dispersion System.
 Fukushima K, Terasaka S, Haraya K, et al
Biol Pharm Bull. 2007 Apr;30(4):733-8.
 Paper
 
Penetration of atazanavir in seminal plasma of men infected with HIV-1.
 van Leeuwen E, Ter Heine R, van der Veen F, et al 
Antimicrob Agents Chemother. 2006 Oct 30;
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
 A prospective evaluation of the effect of atazanavir on the QTc interval and QTc dispersion
in HIV-positive patients.
 Busti AJ, Tsikouris JP, Peeters MJ, et al 
HIV Med. 2006 Jul;7(5):317-22.
 Abstract|
 
Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity:
demonstrable  differences in vitro and clinically.
 Noor MA, Flint OP, Maa JF, Parker RA.  
AIDS. 2006 Sep 11;20(14):1813-21.
 Abstract
 
Review of atazanavir: a novel HIV protease inhibitor.
 Fuster D, Clotet B.
Expert Opin Pharmacother. 2005 Aug;6(9):1565-72.
 Abstract
 
Atazanavir for the treatment of human immunodeficiency virus infection.
 Busti AJ, Hall RG, Margolis DM.
Pharmacotherapy. 2004 Dec;24(12):1732-47.
Abstract
 
Atazanavir
Orrick JJ, Steinhart CR.
Ann Pharmacother. 2004 Sep 7
Abstract

Atazanavir: New Option for Treatment of HIV Infection.
 Havlir DV, O'Marro SD.
Clin Infect Dis. 2004 Jun 1;38(11):1599-604
 Abstract
In Vitro Studies
       
 

Atazanavir: Effects on P-gp transport and CYP3A metabolism in vitro.
 Perloff ES, Duan SX, Skolnik PR, et al 
Drug Metab Dispos. 2005 Mar 11;
 Abstract
Dosage Studies
       
 
A WEEK-IN-REVIEW FEATURED REPORT
 Mid-dosing interval concentration of atazanavir and virological outcome
in patients treated for HIV-1 infection.
 Fabbiani M, Di Giambenedetto S, Ragazzoni E, et al
HIV Med. 2010 Jan 11.
 Abstract

Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in
antiretroviral-naive subjects: 48-week results.
 Murphy RL, Sanne I, Cahn P, et al
AIDS. 2003 Dec 5;17(18):2603-14.
Abstract
Pharmacokinetics
       
 
A WEEK-IN REVIEW FEATURED REPORT
Effects of hepatitis C virus infection on the pharmacokinetics of ritonavir-boosted atazanavir in
HIV-1-infected patients.
Di Biagio A, Rosso R, Loregian A,  et al
J Infect Chemother. 2012 Mar 16
 Abstract

A population pharmacokinetic-pharmacogenetic analysis of atazanavir.
Kile DA, Mawhinney S, Aquilante C,  et al
AIDS Res Hum Retroviruses. 2012 Mar 6
 Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Pharmacokinetics of switching unboosted atazanavir coadministered with tenofovir disoproxil
fumarate from 400 mg once daily to 200 mg twice daily in HIV-positive patients.
Bonora S, Gonzalez de Requena D, D'Avolio A,  et al
Antivir Ther. 2011;16(4):499-504.
 Abstract

Population pharmacokinetics of atazanavir/r in HIV-1 infected children and adolescents.
 Foissac F, Blanche S, Dollfus C, et al  
Br J Clin Pharmacol. 2011 Jun 8.
Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Atazanavir and Atazanavir/Ritonavir Pharmacokinetics in HIV-Infected Infants, Children,
and Adolescents.
 Kiser JJ, Rutstein RM, Samson P, et al
AIDS. 2011 May 21.
 Abstract

Atypical pharmacokinetics of atazanavir in an HIV-1-infected patient.
 Cattaneo D, Meraviglia P, Cozzi V,  et al
Fundam Clin Pharmacol. 2011 Jan 7.
Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Pharmacokinetics and safety of twice-daily atazanavir 300 mg and raltegravir 400 mg in
healthy individuals.
 Zhu L, Butterton J, Persson A, Stonier M,  et al
Antivir Ther. 2010;15(8):1107-14
 Abstract

Population Pharmacokinetic modelling of the association between 63396C->T
Pregnane-X-Receptor (PXR) polymorphism and unboosted atazanavir clearance.
 Schipani A, Siccardi M, D'Avoli, et al
Antimicrob Agents Chemother. 2010 Oct 4.
 Abstract

Pharmacokinetics and Pharmacogenomics of Once Daily Raltegravir and Atazanavir in
Healthy Volunteers.
Neely M, Decosterd L, Fayet A, et al
Antimicrob Agents Chemother. 2010 Sep
Abstract

Pharmacokinetics, protein-binding-adjusted inhibitory quotients for atazanavir/ritonavir
300/100 mg in treatment-naďve HIV-infected patients.
 Lambert-Niclot S, Machouf N, Peytavin G, et al
HIV Med. 2010 May 20.
Abstract

Influence of alpha-1 glycoprotein acid concentrations and variants on atazanavir
pharmacokinetics in HIV-infected patients included in the ANRS 107 trial.
 Barrail-Tran A, Mentré F, Cosson C, et al
Antimicrob Agents Chemother. 2010 Feb;54(2):614-9.
 Abstract

Atazanavir pharmacokinetics in genetically determined CYP3A5 expressors versus
non-expressors.
 Anderson PL, Aquilante CL, Gardner EM, et al 
J Antimicrob Chemother. 2009 Aug
Abstract

FULL-TEXT PDF ARTICLE
 Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers.
 Dickinson L, Boffito M, Back D, et al
J Antimicrob Chemother. 2009 Jun;63(6):1233-43.
 Paper
 
A Low Dose of Ritonavir-Boosted Atazanavir Provides Adequate Pharmacokinetic Parameters in
HIV-1-Infected Thai Adults.
Avihingsanon A, van der Lugt J, Kerr S, et al 
Clin Pharmacol Ther. 2008 Dec 31
 Abstract
 
A WEEK IN REVIEW FEATURED REPORT
Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h
following drug cessation.
Boffito M, Else L, Back D,
Antivir Ther. 2008;13(7):901-7.
 Abstract
 
Population Pharmacokinetics of Atazanavir in Human Immunodeficiency Virus-Infected Patients.
 Solas C, Gagnieu MC, Ravaux I, Drogoul MP, et al 
Ther Drug Monit. 2008 Sep 16.
 Abstract
 
The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by
gender-related co-factors.
 von Hentig N, Babacan E, Lennemann T, et al
 J Antimicrob Chemother. 2008 May 13
Abstract
 
Effects of Acid-reducing agents on the pharmacokinetics of lopinavir/ritonavir and
ritonavir-boosted atazanavir.
Klein CE, Chiu YL, Cai Y, et al
Clin Pharmacol. 2008 May;48(5):553-62.
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
Factors associated with altered pharmacokinetics in substance users and
non-substance users receiving lopinavir and atazanavir.
 Higgins N, Zingman BS, Slish J, et al
Am J Addict. 2007 Nov-Dec;16(6):488-94.
 Abstract
 
WEEK-IN-REVIEW FEATURED REPORT
 Pharmacokinetics of Antiretroviral Regimens Containing Tenofovir Disoproxil Fumarate and
Atazanavir/Ritonavir in Adolescents and Young Adults with HIV Infection - Study ATN056.
 Kiser JJ, Fletcher CV, Flynn PM, et al 
Antimicrob Agents Chemother. 2007 Nov 19;
Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
Beneficial Pharmacokinetic Interaction Between Atazanavir and Lopinavir/Ritonavir.
 Pham PA, Flexner CW, Parsons T, et al 
J Acquir Immune Defic Syndr. 2007 Mar 29;
 Abstract

 A WEEK-IN-REVIEW FEATURED REPORT
Population pharmacokinetics of atazanavir in patients with human immunodeficiency
virus infection.
 Colombo S, Buclin T, Cavassini M, et al 
Antimicrob Agents Chemother. 2006 Aug 28;
 Abstract
 
Virological responses to atazanavir-ritonavir-based regimens: resistance-substitutions
score and pharmacokinetic parameters (Reyaphar study).
Pellegrin I, Breilh D, Ragnaud JM, et al  
Antivir Ther. 2006;11(4):421-9
 Abstract
 
Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmacokinetics
in HIV-infected patients.
 Dailly E, Tribut O, Tattevin P, et  al
Eur J Clin Pharmacol. 2006 Jun 9;
 Abstract
 
Steady-state pharmacokinetics of atazanavir given alone or in combination with
saquinavir hard-gel capsules or amprenavir in HIV-1-infected patients.
 Seminari E, Guffanti M, Villani P, et al 
Eur J Clin Pharmacol. 2005 Jul 23;
 Abstract
 
Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals
receiving highly active antiretroviral therapy.
 Winston A, Bloch M, Carr A,  et al  
J Antimicrob Chemother. 2005 Jul 4
 Abstract

The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in
HIV-seronegative healthy adults.
 Noor MA, Parker RA, O'mara E, et al 
AIDS. 2004 Nov 5;18(16):2137-2144.
 Abstract
Resistance
       
 
A WEEK-IN-REVIEW FEATURED REPORT
Two Different Patterns of Mutations are Involved in the Genotypic Resistance Score for Atazanavir
Boosted Versus Unboosted by Ritonavir in Multiple Failing Patients.
 Santoro MM, Bertoli A, Lorenzini P, et al 
Infection. 2009 Jan 23.
Abstract
 
The HIV-1 protease resistance mutation I50L is associated with resistance to atazanavir and susceptibility to
other protease inhibitorsin multiple mutational contexts.
 Sista P, Wasikowski B, Lecocq P, et al 
J Clin Virol. 2008 May 9
Abstract
 
The Genotypic Inhibitory Quotient: A Predictive Factor of Atazanavir Response in HIV-1-Infected
Treatment-Experienced Patients.
Solas C, Colson P, Ravaux I, et al
J Acquir Immune Defic Syndr. 2008 Jan 11
Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
Virological failure and subsequent resistance profiles in individuals exposed to atazanavir.
 Stebbing J, Nathan B, Jones R, et al  
AIDS. 2007 Aug 20;21(13):1826-8.
Abstract
 
Multidrug resistance 1 polymorphisms and trough concentrations of atazanavir and lopinavir
in patients with HIV.
Ma Q, Brazeau D, Zingman BS, et al  
Pharmacogenomics. 2007 Mar;8(3):227-235.
Abstract
 
Virological responses to atazanavir-ritonavir-based regimens: resistance-substitutions
score and pharmacokinetic parameters (Reyaphar study).
Pellegrin I, Breilh D, Ragnaud JM, et al  
Antivir Ther. 2006;11(4):421-9
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
Clinical validation of atazanavir/ritonavir genotypic resistance score in protease inhibitor-
experienced patients.
 Vora S, Marcelin AG, Gunthard HF, Flandre P, et al  
AIDS. 2006 Jan 2;20(1):35-40
 Abstract
 
Atazanavir Signature I50L Resistance Substitution Accounts for Unique Phenotype of
Increased Susceptibility to Other Protease Inhibitors in a Variety of Human
Immunodeficiency Virus Type 1 Genetic Backbones.
 Weinheimer S, Discotto L, Friborg J, et al
Antimicrob Agents Chemother. 2005 Sep;49(9):3816-24.
 Abstract

Identification of I50L as the Signature Atazanavir (ATV)-Resistance Mutation in
Treatment-Naive HIV-1-Infected Patients Receiving ATV-Containing Regimens.
Colonno R, Rose R, McLaren C, et al 
J Infect Dis. 2004 May 15;189(10):1802-10.
Abstract
Cross Resistance
       
Protease Inhibitors
 
 
Molecular Basis for Increased Susceptibility of Isolates with Atazanavir
Resistance-Conferring Substitution I50L to Other Protease Inhibitors.
 Yanchunas J Jr, Langley DR, et al   
Antimicrob Agents Chemother. 2005 Sep;49(9):3825-32.
 Abstract
Viral Dynamics
       
 
A WEEK-IN-REVIEW FEATURED REPORT
 Differential Effects of Efavirenz, Lopinavir/r, and Atazanavir/r on the Initial Viral Decay
Rate in Treatment Naďve HIV-1-Infected Patients.
 Edén A, Andersson LM, Andersson O, et al A
IDS Res Hum Retroviruses. 2010 May 10.
 Abstract

A WEEK-IN-REVIEW FEATURED REPORT
 Mid-dosing interval concentration of atazanavir and virological outcome
in patients treated for HIV-1 infection.
 Fabbiani M, Di Giambenedetto S, Ragazzoni E, et al
HIV Med. 2010 Jan 11.
 Abstract

Time to virological failure with atazanavir/ritonavir and lopinavir/ritonavir, with or without an
H2-receptor blocker, not significantly different in HIV observational database study.
Keiser PH, Nassar N.
Int J STD AIDS. 2008 Aug;19(8):561-2
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
Virological failure and subsequent resistance profiles in individuals exposed to atazanavir.
 Stebbing J, Nathan B, Jones R, et al  
 AIDS. 2007 Aug 20;21(13):1826-8.
Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
Virological responses to atazanavir-ritonavir-based regimens: resistance-substitutions
score and pharmacokinetic parameters (Reyaphar study).
Pellegrin I, Breilh D, Ragnaud JM, et al  
Antivir Ther. 2006;11(4):421-9
 Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Effect of baseline protease genotype and phenotype on HIV response to atazanavir/ritonavir in
treatment-experienced patients.
Naeger LK, Struble KA.
AIDS. 2006 Apr 4;20(6):847-53
 Abstract
Drug Comparison Studies
       
Atazanavir vs Efavirenz
 
  Open-label randomized multicenter selection study of once daily antiretroviral treatment regimen
comparing ritonavir-boosted atazanavir to efavirenz with fixed-dose abacavir and Lamivudine.
 Honda M, Ishisaka M, Ishizuka N,  et al
 Intern Med. 2011;50(7):699-705.
Abstract

Comparison of Once-Daily Atazanavir With Efavirenz, Each in Combination With
Fixed-Dose Zidovudine and Lamivudine, As Initial Therapy for Patients Infected With HIV.
 Squires K, Lazzarin A, Gatell JM 
J Acquir Immune Defic Syndr. 2004 Aug 15;36(5):1011-1019
 Abstract
 
Atazanavir vs Fosamprenavir
 
  FULL TEXT PDF ARTICLE
Fosamprenavir or atazanavir once daily boosted with ritonavir 100mg, plus
tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT
Smith KY, Weinberg WG, Dejesus E, et aL
AIDS Res Ther. 2008 Mar 28;5(1):5
Paper

Atazanavir vs Lopinavir/Ritonavir
 
 
Economic and Health-related Quality of Life (HRQL) Comparison of Lopinavir/ritonavir (LPV/r) and
Atazanavir plus Ritonavir (ATV+RTV) based Regimens for Antiretroviral Therapy (ART)-Naďve and -
Experienced United Kingdom (UK) Patients in 2011.
Simpson K, Baran R, Collomb D,  et al 
J Med Econ. 2012 May 7.
 Abstract

Pharmacokinetics and inhibitory quotient of atazanavir/ritonavir versus lopinavir/ritonavir in
HIV-infected, treatment-naive patients who participated in the CASTLE Study.
Zhu L, Liao S, Child M, Zhang J,  et al
J Antimicrob Chemother. 2011 Nov 25.
 Abstract

A WEEK IN REVIEW FEATURED REPORT
 Atazanavir and lopinavir with ritonavir alone or in combination: analysis of pharmacokinetic
interaction and predictors of drug exposure.
 Di Giambenedetto S, De Luca A, Villani P, et al
HIV Med. 2008 Apr;9(4):239-45.
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with
multiple virologic failures.
 Johnson M, Grinsztejn B, Rodriguez C, et al 
AIDS. 2006 Mar 21;20(5):711-718.
Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
 Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor
failure: a randomized multinational trial.
 Cohen C, Nieto-Cisneros L, Zala C, et al   
 Curr Med Res Opin. 2005 Oct;21(10):1683-92.
 Abstract
 
Atazanavir/RTV vs Nevirapine
 
  A WEEK-IN-REVIEW FEATURED REPORT
 Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine,
in antiretroviral-naive HIV-1 patients: the ARTEN Trial.
 Soriano V, Arastéh K, Migrone H,  et al
Antivir Ther. 2011;16(3):339-48.
 Abstract
Diagnostics/Monitoring
       
 
Comparison of extraction procedures for assessment of matrix effect for selective and reliable determination of atazanavir in human plasma by LC-ESI-MS/MS.
 Yadav M, Trivedi V, Upadhyay V,
J Chromatogr B Analyt Technol Biomed Life Sci. 2012 Jan 9.
 Abstract

Limited sampling strategies for the estimation of atazanavir daily exposure in HIV-infected patients.
Cattaneo D, Ripamonti D, Baldelli
Fundam Clin Pharmacol. 2011 Nov 2. .
 Abstract

UPLC-MS/MS quantification of nanoformulated ritonavir, indinavir, atazanavir, and efavirenz in
 mouse serum and tissues.
 Huang J, Gautam N, Bathena SP 
JChromatogr B Analyt Technol Biomed Life Sci. 2011 Jul 1
 Abstract

Therapeutic Monitoring and Variability of Atazanavir in HIV-Infected Patients, With and Without
HCV Coinfection, Receiving Boosted or Unboosted Regimens.
Regazzi M, Villani P, Gulminetti R, et al
Ther Drug Monit. 2011 May 4.
 Abstract

Use of serum bilirubin levels as surrogate marker of early virological response to atazanavir-based
antiretroviral therapy.
 Morello J, Alvarez E, Cuenca L, et al
AIDS Res Hum Retroviruses. 2011 Feb 25.
 Abstract

Clinical Evaluation of a Dried Blood Spot Assay for Atazanavir
Van Schooneveld T, Swindells S, Nelson SR, et al
Antimicrob Agents Chemother. 2010 Jul 26.
 Abstract

The relation between treatment outcome and efavirenz, atazanavir or lopinavir
exposure in the NORTHIV trial of treatment-naďve HIV-1 infected patients.
 Josephson F, Andersson MC, Flamholc L, et al
Eur J Clin Pharmacol. 2009 Dec 5.
 Abstract

 

Baseline lipid levels rather than the presence of reported body shape changes determine
the degree of improvement in lipid levels after switching to atazanavir.
 van Vonderen, Gras, Wit, Brinkman, et al
HIV Clin Trials. 2009 May-Jun;10(3):168-80.
Abstract
HPLC-MS method for the simultaneous quantification of the new HIV protease inhibitor darunavir,
and 11 other antiretroviral agents in plasma of HIV-infected patients.
 D'Avolio A, Siccardi M, Sciandra M, et al
 J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Oct 7;
Abstract
 
Monitoring Atazanavir Concentrations With Boosted or Unboosted Regimens in
HIV-Infected Patients in Routine Clinical Practice.
 Moltó J, Santos JR, Valle M, et al  
Ther Drug Monit. 2007 Oct;29(5):648-651.
 Abstract
 
Assessing the Impact of Substance use and Hepatitis Coinfection on Atazanavir and Lopinavir
Trough Concentrations in HIV-Infected Patients During Therapeutic Drug Monitoring.
 Slish J, Ma Q, Zingman BS, et al 
Ther Drug Monit. 2007 Oct;29(5):560-565.
 Abstract
 
Therapeutic drug monitoring of the HIV protease inhibitor atazanavir in clinical practice.
 Cleijsen RM, van de Ende ME, Kroon FP, et al
J Antimicrob Chemother. 2007 Aug 17;
 Abstract
 
Integration of Atazanavir into an Existing Liquid Chromatography UV Method for Protease
Inhibitors: Validation and Application.
 Keil K, Hochreitter J, Difrancesco R, et al
Ther Drug Monit. 2007 Feb;29(1):103-109.
 Abstract
 
A quantitative immunoassay for plasma and intracellular atazanavir: studies of drug
accumulation in cultured T-cells.
 Roucairol C, Azoulay S, Nevers MC, et al 
Antimicrob Agents Chemother. 2006 Nov 20;
 Abstract
 
Full Validation of an Analytical Method for the HIV-Protease Inhibitor Atazanavir in Combination
With 8 Other Antiretroviral Agents and its Applicability to Therapeutic Drug Monitoring.
Rezk NL, Crutchley RD, Yeh RF, Kashuba AD.
Ther Drug Monit. 2006 Aug;28(4):517-25.
 Abstract
 
Simple determination of the HIV protease inhibitor atazanavir in human plasma
by high-performance liquid chromatography with UV detection.
Loregian A, Pagni S, Ballarin E, et al
 J Pharm Biomed Anal. 2006 Jun 7;

Liquid chromatographic assay for the protease inhibitor atazanavir in plasma.
 Sparidans RW, Dost F, Crommentuyn KM, et al  
Biomed Chromatogr. 2005 Jun 14;
Abstract
 
Determination of the new HIV-protease inhibitor atazanavir by liquid chromatography after
solid-phase extraction.
 Colombo S, Guignard N, Marzolini C, et al  
J Chromatogr B Analyt Technol Biomed Life Sci. 2004 Oct 15;810(1):25-34.
 Abstract
 
Simultaneous quantification of the new HIV protease inhibitors atazanavir and tipranavir
in human plasma by high-performance liquid chromatography coupled with electrospray
ionization tandem mass spectrometry.
 Crommentuyn KM, Rosing H, Hillebrand MJ, et al
J Chromatogr B Analyt Technol Biomed Life Sci. 2004 May 25;804(2):359-67
 Abstract
 
Liquid chromatography-tandem mass spectrometric quantitative determination of the HIV
protease inhibitor atazanavir (BMS-232632) in human peripheral blood mononuclear cells
(PBMC): practical approaches to PBMC preparation and PBMC assay design for high-
throughput analysis.
Jemal M, Rao S, Gatz M, Whigan D. 
J Chromatogr B Analyt Technol Biomed Life Sci. 2003 Oct 5;795(2):273-89
 Abstract
 
Quantitative determination of the HIV protease inhibitor atazanavir (BMS-232632) in human
plasma by liquid chromatography-tandem mass spectrometry following automated solid-phase
extraction.
Schuster A, Burzawa S, Jemal M, et al.
Chromatogr B Analyt Technol Biomed Life Sci 2003 May25;788(2):377-86
 Abstract
 
Adverse Events
       
 
Clinical Significance of Hyperbilirubinemia Among HIV-1-Infected Patients Treated with Atazanavir/Ritonavir
Through 96 Weeks in the CASTLE Study.
McDonald C, Uy J, Hu W,  et al
AIDS Patient Care STDS. 2012 Mar 9.
Abstract

Symptomatic Hyperbilirubinemia Secondary to Dapsone Induced Hemolysis and Atazanavir Therapy.
 East J, Blanton LS.
Antimicrob Agents Chemother. 2011 Nov 28.
 Abstract

UGT1A1*28 variant allele is a predictor of severe hyperbilirubinemia in HIV-infected patients on HAART in southern Brazil.
 Turatti L, Sprinz E, Lazzaretti RK, et al
AIDS Res Hum Retroviruses. 2011 Nov 4
 Abstract

Unexpected atazanavir-associated biliary lithiasis in an HIV-infected patient.
Courbon E, Laylavoix F, Soulié C, et al
 J Antimicrob Chemother. 2011 Oct 23.
 Abstract

Short communication: use of serum bilirubin levels as surrogate marker of early virological response to atazanavir-based
antiretroviral therapy.
 Morello J, Alvarez E, Cuenca L, et al
AIDS Res Hum Retroviruses. 2011 Oct;27(10):1043-5.
Abstract

Atazanavir/r exposure is associated with an increased rate of renal stones compared with efavirenz, lopinavir/r and darunavir/r.
 Rockwood N, Mandalia S, Bower M, et al
AIDS. 2011 Jun 29.
Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Development of Buffalo Hump in the course of antiretroviral therapy including raltegravir and
unboosted atazanavir: a case report and review of the literature.
 Ceccarelli G, d'Ettorre G, Marchetti F, et al 
J Med Case Reports. 2011 Feb 17;5(1):70
 Abstract

Chronic interstitial nephritis in an HIV type-1-infected patient receiving ritonavir-boosted atazanavir.
Viglietti D, Verine J, De Castro N,  et al
Antivir Ther. 2011;16(1):119-21.
 Abstract

Impact of atazanavir-based HAART regimen on the carotid intima-media thickness of
HIV-infected persons: a comparative prospective cohort.
de Saint-Martin L, Bressollette L, Perfezou P, et al
AIDS. 2010 Nov 27;24(18):2797-801.
 Abstract

FULL-TEXT ARTICLE
 Incidence of Atazanavir-associated Hyperbilirubinemia in Korean HIV Patients: 30 Months
Follow-up Results in a Population with Low UDP-glucuronosyltransferase1A1*28 Allele
Frequency.
Choe PG, Park WB, Song JS, et al
J Korean Med Sci. 2010 Oct;25(10):1427-30.
 Paper

A WEEK-IN-REVIEW FEATURED REPORT
Lipid profiles in HIV-infected adults receiving atazanavir and atazanavir/ritonavir:
systematic review and meta-analysis of randomized controlled trials.
 Carey D, Amin J, Boyd M, Petoumenos K, Emery S.
 J Antimicrob Chemother. 2010 Jun 16
 Abstract

Adverse Reactions of Atazanavir, Fosamprenavir and Tipranavir in "Real Life"
 Balayssac E, Autret-Leca E, Jonville-Béra AP, et al
Therapie. 2010 3-4;65(2):121-128.
Abstract

Renal toxicity associated with tenofovir use.
Rodriguez-Nóvoa S, Alvarez E, Labarga P, Soriano V.
Expert Opin Drug Saf. 2010 Apr 13.
 Abstract

Impact of Ritonavir, Atazanavir and their Combination on the CYP3A4 Induction Potential
of Efavirenz in Primary Human Hepatocytes.
Mugundu GM, Hariparsad N, Desai PB. 
Drug Metab Lett. 2010 Mar 4.
Abstract

Atazanavir-Associated Choledocholithiasis Leading to Acute Hepatitis in an
HIV-Infected Adult
Jacques AC, Gigučre P, Zhang G,
Ann Pharmacother. 2009 Dec 2
 Abstract

Hyperbilirubinemia during Atazanavir Treatment in 2,404 Patients in the Italian Atazanavir
Expanded Access Program and MASTER Cohorts.
 Torti C, Lapadula G, Antinori A, et al
Infection. 2009 May 26.
Abstract

Iatrogenic Cushing's syndrome, diabetes mellitus and secondary adrenal failure in a human
immunodeficiency virus patient treated with ritonavir boosted atazanavir and fluticasone.
 Collet-Gaudillat C, Roussin-Bretagne S, Desforges-Bullet V, et al 
Ann Endocrinol (Paris). 2009 May 4.
Abstract
 
Effect of atazanavir versus other protease inhibitor-containing antiretroviral therapy on endothelial function in
HIV-infected persons: Randomized controlled trial.
 Flammer AJ, T T Vo N, Ledergerber B, et al
 Heart. 2008 Jul 24.
 Abstract
 
Case presentation: nephrolithiasis in a patient treated with atazanavir.
 Savini C, James C, Wilson S, et al 
J Assoc Nurses AIDS Care. 2008 May-Jun;19(3):225-7."
 Abstract
 
A WEEK IN REVIEW FEATURED REPORT
Liver toxicity of antiretroviral combinations including atazanavir/ritonavir in patients
co-infected with HIV and hepatitis viruses: impact of pre-existing liver fibrosis.
 Pineda JA, Santos J, Rivero A, et al 
J Antimicrob Chemother. 2008 Feb 14
Abstract
 
Urolithiasis in HIV-positive patients treated with atazanavir
 Couzigou C, Daudon M, Meynard JL,  
Clin Infect Dis. 2007 Oct 15;45(8):e105-8
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
Insulin resistance in HIV-infected patients receiving long-term therapy with efavirenz,
lopinavir/ritonavir and atazanavir.
 Bernal E, Masiá M, Padilla S, et al
Med Clin (Barc). 2007 Jul 14;129(7):252-4.
 Abstract
 
Cushing Syndrome and Severe Adrenal Suppression Caused by Fluticasone and Protease
Inhibitor Combination in an HIV-Infected Adolescent.
 St Germain RM, Yigit S, Wells L, et al 
AIDS Patient Care STDS. 2007 Jun;21(6):373-7.
 Abstract
 
Gilbert's disease and atazanavir: from phenotype to UDP-glucuronosyltransferase haplotype.
 Lankisch TO, Moebius U, Wehmeier M, et al 
Hepatology. 2006 Nov;44(5):1324-32.
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
 (Renal failure in a patient treated with atazanavir}
Moddel M, Pfammatter R, Varga Z, Keusch G. 
Schweiz Rundsch Med Prax. 2006 Jun 7;95(23):949-51.
 Abstract

Body Fat and Other Metabolic Effects of Atazanavir and Efavirenz, Each Administered in
Combination with Zidovudine plus Lamivudine, in Antiretroviral-Naive HIV-Infected Patients.
Jemsek JG, Arathoon E, Arlotti M, et al
Clin Infect Dis. 2006 Jan 15;42(2):273-80.
 Abstract
 
Can boosted atazanavir induce hyperlipotrophy?
 Dellamonica P.  
 J Infect. 2005 Oct 17;
Abstract
 
Acute interstitial nephritis associated with atazanavir, a new protease inhibitor.
 Brewster UC, Perazella MA. 
Am J Kidney Dis. 2004 Nov;44(5):e81-4
 Abstract

Does atazanavir cause lipodystrophy?
Gazzard BG, Moyle G.
J HIV Ther. 2004 May;9(2):41-4
 Abstract
Adherence
       
 
A WEEK-IN-REVIEW FEATURED REPORT
Use of bilirubin as a marker of adherence to atazanavir-based antiretroviral therapy.
 Petersen K, Riddle MS, Jones LE, et al  
AIDS. 2005 Oct 14;19(15):1700-2.
 Abstract
Economics
       
 
Cost effectiveness of atazanavir-ritonavir versus lopinavir-ritonavir in treatment-naive human immunodeficiency virus-infected
patients in the United States.
 Broder MS, Chang EY, Bentley TG, Juday T, Uy J.
J Med Econ. 2011 Feb 2.
Abstract

Cost-effectiveness of atazanavir/ritonavir compared with lopinavir/ritonavir in treatment-naďve
human immunodeficiency virus-1 patients in Sweden.
 Thuresson PO, Heeg B, Lescrauwaet B,  et al
 Scand J Infect Dis. 2011 Jan 13
 Abstract
Pharmacogenetics
       
 
A population pharmacokinetic-pharmacogenetic analysis of atazanavir.
Kile DA, Mawhinney S, Aquilante C,  et a
AIDS Res Hum Retroviruses. 2012 Mar 6
 Abstract

 

Atazanavir Main Page New/Newsworthy Home Page      

Atazanavir Journal Citations